Patent intelligence · CN
CN 117980330
Homodimeric peptides and antibodies comprising same
Homodimeric peptides and antibodies comprising same
Patent details — CN 117980330
- Jurisdiction
- CN
- Status
- granted
- Grant date
- May 3, 2024
- Expiration
- Apr 28, 2044
- Applicant
- PAXTRADIA MAB SCIENCE AB
- CPC classes
- A61K 47/ 64 A I, A61P 9/ 00 A I, A61P 25/ 28 A I, A61P 29/ 00 A I
Quick answer
CN 117980330 (Homodimeric peptides and antibodies comprising same) is held by PAXTRADIA MAB SCIENCE AB. Status: granted. Granted May 3, 2024. Expires Apr 28, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PAXTRADIA MAB SCIENCE AB
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 47/ 64 A I, A61P 9/ 00 A I, A61P 25/ 28 A I, A61P 29/ 00 A I, A61P 35/ 00 A I, A61P 37/ 06 A I
More from PAXTRADIA MAB SCIENCE AB
Related pharmaceutical patents in our USPTO index.
-
WO 2025027051
INHIBITEURS DE SPHINGOSINE-1-PHOSPHATE LYASE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
granted -
WO 2024175803
COMPOSÉS POUR LE TRAITEMENT DE MALADIES MYÉLOÏDES AVEC DES ANOMALIES CHROMOSOMIQUES
granted -
WO 2024146923
INHIBITEURS DE POLYMÉRISATION DE TUBULINE
granted -
CA 3217490
MASITINIB POUR LE TRAITEMENT DU CANCER DE LA PROSTATE RESISTANT A LA CASTRATION
granted -
WO 2022234069
NOUVEAUX DÉRIVÉS DE 2-AMINOOXAZOLE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES INFECTIEUSES
granted -
CA 3201259
MASITINIB POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
granted -
CA 3174748
UTILISATION DE MASITINIB POUR LE TRAITEMENT DE LA MALADIE A CORONAVIRUS 2019 (COVID-19)
granted
Frequently asked questions
What is US patent 117980330?
CN 117980330 (Homodimeric peptides and antibodies comprising same) is held by PAXTRADIA MAB SCIENCE AB. Status: granted. Granted May 3, 2024. Expires Apr 28, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CN 117980330?
PAXTRADIA MAB SCIENCE AB is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CN 117980330 expire?
Our index shows an expiration date of Apr 28, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.